0001562180-24-004011.txt : 20240514
0001562180-24-004011.hdr.sgml : 20240514
20240514073029
ACCESSION NUMBER: 0001562180-24-004011
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240513
FILED AS OF DATE: 20240514
DATE AS OF CHANGE: 20240514
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CHILDS JOHN W
CENTRAL INDEX KEY: 0001027035
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41477
FILM NUMBER: 24941454
MAIL ADDRESS:
STREET 1: 111 HUNTINGTON AVENUE
STREET 2: SUITE 2900
CITY: BOSTON
STATE: MA
ZIP: 02199
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Biohaven Ltd.
CENTRAL INDEX KEY: 0001935979
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: D8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
BUSINESS PHONE: 203-404-0410
MAIL ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
FORMER COMPANY:
FORMER CONFORMED NAME: Biohaven Research Ltd.
DATE OF NAME CHANGE: 20220629
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2024-05-13
false
0001935979
Biohaven Ltd.
BHVN
0001027035
CHILDS JOHN W
C/O BIOHAVEN LTD.
215 CHURCH STREET
NEW HAVEN
CT
06510
true
false
false
false
false
Common Shares
2024-05-13
4
P
false
28500.00
35.1744
A
2283341.00
I
By John W Childs 2013 Revocable Trust
Common Shares
24391.00
I
By 1994 Charitable Remainder Trust
Common Shares
4096512.00
I
By 2021 B-H Charitable Remainder Trust
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.00 - $35.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
/s/ George Clark, Attorney-in-Fact
2024-05-14